## SCORE Search Results Details for Application 10552515 and Search Result 20090316\_151740\_us-10-552-515-1\_copy\_157\_933 oligo8.rag

 Score Home
 Retrieve Application
 SCORE System
 SCORE
 Comments /

 Page
 List
 Overview
 FAQ
 Suggestions

This page gives you Search Results detail for the Application 10552515 and Search Result 20090316\_151740\_us-10-552-515-1\_copy\_157\_933.oligo8.rag.

Go Back to previous page

GenCore version 6.3 Copyright (c) 1993 - 2009 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: March 17, 2009, 20:56:54; Search time 133 Seconds

(without alignments)

4899.431 Million cell updates/sec

Title: US-10-552-515-1\_COPY\_157\_933

Perfect score: 777

Sequence: 1 QQDVQDGNTTVHYALLSASW.....SELSSHWTPFTVPKASQLQQ 777

Scoring table: OLIGO

Gapop 60.0 , Gapext 60.0

Searched: 4548778 seqs, 838641292 residues

Word size: 8

Total number of hits satisfying chosen parameters: 11

Minimum DB seq length: 8
Maximum DB seq length: 10

Post-processing: Listing first 45 summaries

Database: A\_Geneseq\_200812:\*

1: geneseqp:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result		% Query				
No.	Score	Match	Length	DB 	ID	Description
1	9	1.2	9	1	ADT77668	Adt77668 Splice va
2	9	1.2	9	1	ADT77673	Adt77673 Splice va
3	9	1.2	9	1	ADT77670	Adt77670 Splice va
4	9	1.2	9	1	ADT77671	Adt77671 Splice va
5	9	1.2	9	1	ADT77666	Adt77666 Splice va
6	9	1.2	9	1	ADT77669	Adt77669 Splice va
7	9	1.2	9	1	ADT77672	Adt77672 Splice va
8	9	1.2	9	1	ADT77667	Adt77667 Splice va
9	8	1.0	10	1	AAG95042	Aag95042 Human com
10	8	1.0	10	1	AAG97554	Aag97554 Human com
11	8	1.0	10	1	AAG97553	Aag97553 Human com

## ALIGNMENTS

```
RESULT 1
ADT77668
ID
     ADT77668 standard; peptide; 9 AA.
XX
AC
     ADT77668;
XX
DT
     13-JAN-2005 (first entry)
XX
     Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.
DE
XX
ΚW
     Splice variant-novel gene expressed in prostate; SV-NGEP; human;
     prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
ΚW
XX
     Homo sapiens.
OS
XX
PN
     WO2004092213-A1.
XX
     28-OCT-2004.
PD
XX
PF
     05-APR-2004; 2004WO-US010588.
XX
PR
     08-APR-2003; 2003US-0461399P.
XX
     (USSH ) US DEPT HEALTH & HUMAN SERVICES.
PA
XX
PΙ
     Pastan I, Bera TK, Lee B;
XX
     WPI; 2004-758338/74.
DR
XX
```

```
New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
PΤ
     encoding nucleic acid molecule for diagnosing, preventing or treating
PΤ
PΤ
     cancer, especially prostate cancer.
XX
     Disclosure; SEQ ID NO 5; 88pp; English.
PS
XX
CC
     The present sequence is that of a predicted epitope of human splice
CC
     variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
CC
     is predicted to bind HLA2-01 and was identified using an HLA binding
CC
     motif program. It corresponds to amino acids 170-178 of SV-NGEP.
CC
     Polypeptides comprising an immunogenic fragment of 8 consecutive amino
     acids of SV-NGEP which specifically bind to an antibody that specifically
CC
     binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
CC
CC
     claimed. The invention provides methods for: detecting prostate cancer in
     a subject by contacting a sample with an antibody that specifically binds
CC
     a SV-NGEP polypeptide and detecting the formation of an immune complex,
CC
CC
     or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
     producing an immune response against a cell expressing SV-NGEP, for
CC
CC
     example in a subject with prostate cancer, by administering SV-NGEP
CC
     polypeptide or polynucleotide to produce an immune response that
     decreases growth of the prostate cancer; inhibiting the growth of a
CC
CC
     malignant cell that expresses SV-NGEP by culturing cytotoxic T
CC
     lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
CC
     these with the malignant cell; and inhibiting the growth of a malignant
     cell by contact with an antibody that specifically binds SV-NGEP, where
CC
CC
     the antibody is linked to a chemotherapeutic agent or toxin.
XX
SO
     Sequence 9 AA;
                           1.2%; Score 9; DB 1; Length 9;
 Query Match
 Best Local Similarity 100.0%; Pred. No. 3.9e+06;
 Matches
             9; Conservative 0; Mismatches 0; Indels
                                                                 0;
                                                                             0;
                                                                     Gaps
          14 ALLSASWAV 22
Qу
              Db
            1 ALLSASWAV 9
RESULT 2
ADT77673
     ADT77673 standard; peptide; 9 AA.
ID
XX
АC
    ADT77673;
XX
     13-JAN-2005 (first entry)
\mathsf{DT}
XX
     Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.
DE
XX
     Splice variant-novel gene expressed in prostate; SV-NGEP; human;
KW
```

```
ΚW
     prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
XX
OS
     Homo sapiens.
XX
PN
     WO2004092213-A1.
XX
PD
     28-OCT-2004.
XX
PF
     05-APR-2004; 2004WO-US010588.
XX
PR
     08-APR-2003; 2003US-0461399P.
XX
PA
     (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PΙ
    Pastan I, Bera TK, Lee B;
XX
     WPI; 2004-758338/74.
DR
XX
PT
     New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
PΤ
     encoding nucleic acid molecule for diagnosing, preventing or treating
PT
     cancer, especially prostate cancer.
XX
PS
     Disclosure; SEQ ID NO 10; 88pp; English.
XX
CC
     The present sequence is that of a predicted epitope of human splice
     variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
CC
CC
     is predicted to bind HLA2-01 and was identified using an HLA binding
CC
     motif program. It corresponds to amino acids 562-570 of SV-NGEP.
CC
     Polypeptides comprising an immunogenic fragment of 8 consecutive amino
     acids of SV-NGEP which specifically bind to an antibody that specifically
CC
CC
     binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
CC
     claimed. The invention provides methods for: detecting prostate cancer in
     a subject by contacting a sample with an antibody that specifically binds
CC
     a SV-NGEP polypeptide and detecting the formation of an immune complex,
CC
CC
     or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
CC
     producing an immune response against a cell expressing SV-NGEP, for
CC
     example in a subject with prostate cancer, by administering SV-NGEP
CC
     polypeptide or polynucleotide to produce an immune response that
CC
     decreases growth of the prostate cancer; inhibiting the growth of a
     malignant cell that expresses SV-NGEP by culturing cytotoxic T
CC
CC
     lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
     these with the malignant cell; and inhibiting the growth of a malignant
CC
CC
     cell by contact with an antibody that specifically binds SV-NGEP, where
     the antibody is linked to a chemotherapeutic agent or toxin.
CC
XX
SQ
     Sequence 9 AA;
 Query Match
                          1.2%; Score 9; DB 1; Length 9;
```

Best Local Similarity 100.0%; Pred. No. 3.9e+06;

Matches

```
9; Conservative 0; Mismatches
                                                   0; Indels
                                                                 0;
                                                                             0;
                                                                     Gaps
Qу
         406 KIYVSLAHV 414
              Db
            1 KIYVSLAHV 9
RESULT 3
ADT77670
ID
     ADT77670 standard; peptide; 9 AA.
XX
AC
    ADT77670;
XX
     13-JAN-2005 (first entry)
DT
XX
     Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.
DE
XX
     Splice variant-novel gene expressed in prostate; SV-NGEP; human;
KW
     prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
ΚW
XX
OS
     Homo sapiens.
XX
PN
     WO2004092213-A1.
XX
PD
     28-OCT-2004.
XX
PF
     05-APR-2004; 2004WO-US010588.
XX
PR
     08-APR-2003; 2003US-0461399P.
XX
PA
     (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PΙ
     Pastan I, Bera TK, Lee B;
XX
     WPI; 2004-758338/74.
DR
XX
PΤ
     New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
     encoding nucleic acid molecule for diagnosing, preventing or treating
PT
PT
     cancer, especially prostate cancer.
XX
ΡS
     Disclosure; SEQ ID NO 7; 88pp; English.
XX
CC
     The present sequence is that of a predicted epitope of human splice
     variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
CC
     is predicted to bind HLA2-01 and was identified using an HLA binding
CC
CC
     motif program. It corresponds to amino acids 557-565 of SV-NGEP.
     Polypeptides comprising an immunogenic fragment of 8 consecutive amino
CC
     acids of SV-NGEP which specifically bind to an antibody that specifically
CC
CC
     binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
```

```
claimed. The invention provides methods for: detecting prostate cancer in
CC
     a subject by contacting a sample with an antibody that specifically binds
CC
     a SV-NGEP polypeptide and detecting the formation of an immune complex,
CC
CC
     or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
CC
     producing an immune response against a cell expressing SV-NGEP, for
     example in a subject with prostate cancer, by administering SV-NGEP
CC
CC
     polypeptide or polynucleotide to produce an immune response that
CC
     decreases growth of the prostate cancer; inhibiting the growth of a
CC
     malignant cell that expresses SV-NGEP by culturing cytotoxic T
     lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
CC
CC
     these with the malignant cell; and inhibiting the growth of a malignant
     cell by contact with an antibody that specifically binds SV-NGEP, where
CC
CC
     the antibody is linked to a chemotherapeutic agent or toxin.
XX
SQ
     Sequence 9 AA;
                           1.2%; Score 9; DB 1; Length 9;
 Query Match
 Best Local Similarity 100.0%; Pred. No. 3.9e+06;
 Matches
             9; Conservative 0; Mismatches 0; Indels
                                                                 0;
                                                                             0;
                                                                     Gaps
         401 ILILSKIYV 409
Qу
              Db
            1 ILILSKIYV 9
RESULT 4
ADT77671
     ADT77671 standard; peptide; 9 AA.
ID
XX
АC
    ADT77671;
XX
DT
     13-JAN-2005 (first entry)
XX
     Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.
\mathsf{DE}
XX
     Splice variant-novel gene expressed in prostate; SV-NGEP; human;
KW
    prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
KW
XX
OS
     Homo sapiens.
XX
PN
     WO2004092213-A1.
XX
PD
     28-OCT-2004.
XX
PF
     05-APR-2004; 2004WO-US010588.
XX
PR
     08-APR-2003; 2003US-0461399P.
XX
PA
     (USSH ) US DEPT HEALTH & HUMAN SERVICES.
```

```
XX
PΙ
     Pastan I, Bera TK, Lee B;
XX
     WPI; 2004-758338/74.
DR
XX
PT
     New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
PT
     encoding nucleic acid molecule for diagnosing, preventing or treating
     cancer, especially prostate cancer.
PT
XX
PS
     Disclosure; SEQ ID NO 8; 88pp; English.
XX
CC
     The present sequence is that of a predicted epitope of human splice
     variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
CC
CC
     is predicted to bind HLA2-01 and was identified using an HLA binding
     motif program. It corresponds to amino acids 258-266 of SV-NGEP.
CC
     Polypeptides comprising an immunogenic fragment of 8 consecutive amino
CC
     acids of SV-NGEP which specifically bind to an antibody that specifically
CC
     binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
CC
CC
     claimed. The invention provides methods for: detecting prostate cancer in
CC
     a subject by contacting a sample with an antibody that specifically binds
CC
     a SV-NGEP polypeptide and detecting the formation of an immune complex,
CC
     or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
     producing an immune response against a cell expressing SV-NGEP, for
CC
CC
     example in a subject with prostate cancer, by administering SV-NGEP
     polypeptide or polynucleotide to produce an immune response that
CC
     decreases growth of the prostate cancer; inhibiting the growth of a
CC
CC
     malignant cell that expresses SV-NGEP by culturing cytotoxic T
     lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
CC
CC
     these with the malignant cell; and inhibiting the growth of a malignant
     cell by contact with an antibody that specifically binds SV-NGEP, where
CC
CC
     the antibody is linked to a chemotherapeutic agent or toxin.
XX
     Sequence 9 AA;
SO
                           1.2%; Score 9; DB 1;
 Query Match
                                                   Length 9;
 Best Local Similarity 100.0%; Pred. No. 3.9e+06;
 Matches
            9;
                Conservative 0; Mismatches 0;
                                                       Indels
                                                                 0;
                                                                     Gaps
                                                                             0;
Qу
          102 ILFEILAKT 110
              Db
            1 ILFEILAKT 9
RESULT 5
ADT77666
    ADT77666 standard; peptide; 9 AA.
ID
XX
АC
    ADT77666;
XX
```

```
13-JAN-2005 (first entry)
DT
XX
     Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.
\mathsf{DE}
XX
     Splice variant-novel gene expressed in prostate; SV-NGEP; human;
KW
     prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
KW
XX
     Homo sapiens.
OS
XX
PN
     WO2004092213-A1.
XX
     28-OCT-2004.
PD
XX
PF
     05-APR-2004; 2004WO-US010588.
XX
PR
     08-APR-2003; 2003US-0461399P.
XX
PΑ
     (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PΙ
     Pastan I, Bera TK, Lee B;
XX
DR
     WPI; 2004-758338/74.
XX
PΤ
     New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
     encoding nucleic acid molecule for diagnosing, preventing or treating
PΤ
PT
     cancer, especially prostate cancer.
XX
PS
     Disclosure; SEQ ID NO 3; 88pp; English.
XX
CC
     The present sequence is that of a predicted epitope of human splice
CC
     variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
CC
     is predicted to bind HLA2-01 and was identified using an HLA binding
     motif program. It corresponds to amino acids 427-435 of SV-NGEP.
CC
     Polypeptides comprising an immunogenic fragment of 8 consecutive amino
CC
CC
     acids of SV-NGEP which specifically bind to an antibody that specifically
CC
     binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
CC
     claimed. The invention provides methods for: detecting prostate cancer in
CC
     a subject by contacting a sample with an antibody that specifically binds
CC
     a SV-NGEP polypeptide and detecting the formation of an immune complex,
     or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
CC
```

the antibody is linked to a chemotherapeutic agent or toxin.

producing an immune response against a cell expressing SV-NGEP, for example in a subject with prostate cancer, by administering SV-NGEP

lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting

these with the malignant cell; and inhibiting the growth of a malignant

cell by contact with an antibody that specifically binds SV-NGEP, where

polypeptide or polynucleotide to produce an immune response that decreases growth of the prostate cancer; inhibiting the growth of a

malignant cell that expresses SV-NGEP by culturing cytotoxic T

CC

CC CC

CC

CC CC

CC

CC

CC

The present sequence is that of a predicted epitope of human splice

variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope

Disclosure; SEQ ID NO 6; 88pp; English.

PS XX CC

CC

```
CC
     is predicted to bind HLA2-01 and was identified using an HLA binding
CC
     motif program. It corresponds to amino acids 846-854 of SV-NGEP.
     Polypeptides comprising an immunogenic fragment of 8 consecutive amino
CC
CC
     acids of SV-NGEP which specifically bind to an antibody that specifically
CC
     binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
     claimed. The invention provides methods for: detecting prostate cancer in
CC
CC
     a subject by contacting a sample with an antibody that specifically binds
CC
     a SV-NGEP polypeptide and detecting the formation of an immune complex,
CC
     or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
     producing an immune response against a cell expressing SV-NGEP, for
CC
CC
     example in a subject with prostate cancer, by administering SV-NGEP
     polypeptide or polynucleotide to produce an immune response that
CC
     decreases growth of the prostate cancer; inhibiting the growth of a
CC
CC
     malignant cell that expresses SV-NGEP by culturing cytotoxic T
     lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
CC
     these with the malignant cell; and inhibiting the growth of a malignant
CC
CC
     cell by contact with an antibody that specifically binds SV-NGEP, where
     the antibody is linked to a chemotherapeutic agent or toxin.
CC
XX
SQ
     Sequence 9 AA;
 Query Match
                           1.2%; Score 9; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 3.9e+06;
 Matches
            9; Conservative 0; Mismatches 0;
                                                       Indels
                                                                 0;
                                                                     Gaps
                                                                             0;
          690 LLAIRLAFV 698
Qу
              Db
            1 LLAIRLAFV 9
RESULT 7
ADT77672
     ADT77672 standard; peptide; 9 AA.
ID
XX
АC
    ADT77672;
XX
DT
     13-JAN-2005 (first entry)
XX
DE
     Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.
XX
     Splice variant-novel gene expressed in prostate; SV-NGEP; human;
KW
     prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
KW
XX
OS
    Homo sapiens.
XX
    WO2004092213-A1.
PN
XX
PD
     28-OCT-2004.
XX
```

```
PF
     05-APR-2004; 2004WO-US010588.
XX
     08-APR-2003; 2003US-0461399P.
PR
XX
     (USSH ) US DEPT HEALTH & HUMAN SERVICES.
PA
XX
PΙ
     Pastan I, Bera TK, Lee B;
XX
     WPI: 2004-758338/74.
DR
XX
PT
     New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
     encoding nucleic acid molecule for diagnosing, preventing or treating
PΤ
PT
     cancer, especially prostate cancer.
XX
     Disclosure; SEQ ID NO 9; 88pp; English.
PS
XX
CC
     The present sequence is that of a predicted epitope of human splice
CC
     variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
CC
     is predicted to bind HLA2-01 and was identified using an HLA binding
CC
     motif program. It corresponds to amino acids 403-411 of SV-NGEP.
CC
     Polypeptides comprising an immunogenic fragment of 8 consecutive amino
CC
     acids of SV-NGEP which specifically bind to an antibody that specifically
CC
     binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
CC
     claimed. The invention provides methods for: detecting prostate cancer in
     a subject by contacting a sample with an antibody that specifically binds
CC
     a SV-NGEP polypeptide and detecting the formation of an immune complex,
CC
CC
     or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
CC
     producing an immune response against a cell expressing SV-NGEP, for
CC
     example in a subject with prostate cancer, by administering SV-NGEP
CC
     polypeptide or polynucleotide to produce an immune response that
CC
     decreases growth of the prostate cancer; inhibiting the growth of a
CC
     malignant cell that expresses SV-NGEP by culturing cytotoxic T
CC
     lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
     these with the malignant cell; and inhibiting the growth of a malignant
CC
CC
     cell by contact with an antibody that specifically binds SV-NGEP, where
CC
     the antibody is linked to a chemotherapeutic agent or toxin.
XX
SQ
     Sequence 9 AA;
                           1.2%; Score 9; DB 1; Length 9;
 Query Match
 Best Local Similarity 100.0%; Pred. No. 3.9e+06;
             9; Conservative 0; Mismatches 0;
 Matches
                                                       Indels
                                                                 0;
                                                                     Gaps
                                                                             0;
          247 WLLSSACAL 255
Qу
              Db
           1 WLLSSACAL 9
```

RESULT 8

```
ADT77667
     ADT77667 standard; peptide; 9 AA.
ID
XX
АC
     ADT77667;
XX
DT
     13-JAN-2005 (first entry)
XX
     Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.
DE
XX
KW
     Splice variant-novel gene expressed in prostate; SV-NGEP; human;
KW
     prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
XX
OS
     Homo sapiens.
XX
     WO2004092213-A1.
PN
XX
PD
     28-OCT-2004.
XX
ΡF
     05-APR-2004; 2004WO-US010588.
XX
     08-APR-2003; 2003US-0461399P.
PR
XX
PA
     (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PΙ
    Pastan I, Bera TK, Lee B;
XX
     WPI; 2004-758338/74.
DR
XX
PT
     New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
     encoding nucleic acid molecule for diagnosing, preventing or treating
PΤ
     cancer, especially prostate cancer.
PΤ
XX
PS
     Disclosure; SEQ ID NO 4; 88pp; English.
XX
CC
     The present sequence is that of a predicted epitope of human splice
CC
     variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
CC
     is predicted to bind HLA2-01 and was identified using an HLA binding
CC
     motif program. It corresponds to amino acids 215-223 of SV-NGEP.
CC
     Polypeptides comprising an immunogenic fragment of 8 consecutive amino
CC
     acids of SV-NGEP which specifically bind to an antibody that specifically
     binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
CC
     claimed. The invention provides methods for: detecting prostate cancer in
CC
CC
     a subject by contacting a sample with an antibody that specifically binds
     a SV-NGEP polypeptide and detecting the formation of an immune complex,
CC
     or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
CC
CC
     producing an immune response against a cell expressing SV-NGEP, for
CC
     example in a subject with prostate cancer, by administering SV-NGEP
CC
     polypeptide or polynucleotide to produce an immune response that
CC
     decreases growth of the prostate cancer; inhibiting the growth of a
```

```
malignant cell that expresses SV-NGEP by culturing cytotoxic T
CC
     lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
CC
    these with the malignant cell; and inhibiting the growth of a malignant
CC
    cell by contact with an antibody that specifically binds SV-NGEP, where
CC
CC
     the antibody is linked to a chemotherapeutic agent or toxin.
XX
SQ
    Sequence 9 AA;
 Query Match
                          1.2%; Score 9; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 3.9e+06;
           9; Conservative 0; Mismatches 0; Indels
                                                                0; Gaps
                                                                             0;
          59 VLLEVVPDV 67
Qу
             1 VLLEVVPDV 9
Db
RESULT 9
AAG95042
ID
    AAG95042 standard; peptide; 10 AA.
XX
АC
    AAG95042;
XX
DT
    18-SEP-2001 (first entry)
XX
    Human complementary peptide, SEQ ID NO: 1236.
DE
XX
    Human; complementary peptide; ligand; drug discovery; drug design.
KW
XX
OS
    Homo sapiens.
XX
PN
    WO200142277-A2.
XX
PD
    14-JUN-2001.
XX
PF
     13-DEC-2000; 2000WO-GB004776.
XX
PR
    13-DEC-1999; 99GB-00029464.
XX
PΑ
     (PROT-) PROTEOM LTD.
XX
PΙ
    Roberts GW, Heal JR;
XX
DR
    WPI; 2001-408419/43.
XX
    A set of peptide ligands consisting of specific complementary peptides to
PΤ
    proteins encoded by genes of the human genome, useful in an assay for
PT
PT
    screening and identifying of one or more novel peptides which are drug
    candidates or pro-drugs.
PΤ
```

```
XX
PS
     Example 4; Page 217; 646pp; English.
XX
CC
     The invention relates to a set of complementary peptide ligands generated
CC
     from the human genome. The complementary peptides interact with their
     relevant target proteins encoded in the human genome. They can be used as
CC
CC
     reagents in drug discovery and as lead ligands to facilitate drug design
CC
     and development. The present sequence is a complementary peptide provided
CC
     in the specification
XX
SQ
     Sequence 10 AA;
 Query Match
                           1.0%; Score 8; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 8.6;
            8; Conservative 0; Mismatches
 Matches
                                                   0; Indels
                                                                 0;
                                                                     Gaps
                                                                             0;
         525 AGASAGAS 532
Qу
              Db
            1 AGASAGAS 8
RESULT 10
AAG97554
ID
    AAG97554 standard; peptide; 10 AA.
XX
                                                Does not bind MHC
                                                               /LBG/
АC
    AAG97554;
XX
DT
     18-SEP-2001 (first entry)
XX
     Human complementary peptide, SEQ ID NO: 3749.
DE
XX
KW
     Human; complementary peptide; ligand; drug discovery; drug design.
XX
OS
     Homo sapiens.
XX
PN
     WO200142277-A2.
XX
PD
     14-JUN-2001.
XX
PF
     13-DEC-2000; 2000WO-GB004776.
XX
PR
     13-DEC-1999; 99GB-00029464.
XX
     (PROT-) PROTEOM LTD.
PA
XX
PΙ
    Roberts GW, Heal JR;
XX
DR
    WPI; 2001-408419/43.
XX
```

```
A set of peptide ligands consisting of specific complementary peptides to
PΤ
     proteins encoded by genes of the human genome, useful in an assay for
PΤ
     screening and identifying of one or more novel peptides which are drug
PΤ
     candidates or pro-drugs.
PT
XX
PS
     Example 6; Page 581; 646pp; English.
XX
     The invention relates to a set of complementary peptide ligands generated
CC
CC
     from the human genome. The complementary peptides interact with their
     relevant target proteins encoded in the human genome. They can be used as
CC
CC
     reagents in drug discovery and as lead ligands to facilitate drug design
     and development. The present sequence is a complementary peptide provided
CC
CC
     in the specification
XX
SQ
     Sequence 10 AA;
 Query Match
                           1.0%; Score 8; DB 1;
                                                   Length 10;
 Best Local Similarity 100.0%; Pred. No. 8.6;
 Matches
             8; Conservative 0; Mismatches
                                                        Indels
                                                                              0;
                                                   0;
                                                                  0;
                                                                      Gaps
          525 AGASAGAS 532
Qу
              Db
            1 AGASAGAS 8
RESULT 11
AAG97553
     AAG97553 standard; peptide; 10 AA.
ID
XX
                                                   Does not bind MHC
                                                                   /LBG/
АC
    AAG97553;
XX
DT
     18-SEP-2001 (first entry)
XX
\mathsf{DE}
     Human complementary peptide, SEQ ID NO: 3748.
XX
     Human; complementary peptide; ligand; drug discovery; drug design.
KW
XX
OS
     Homo sapiens.
XX
PΝ
     WO200142277-A2.
XX
PD
     14-JUN-2001.
XX
PF
     13-DEC-2000; 2000WO-GB004776.
XX
     13-DEC-1999;
                    99GB-00029464.
PR
XX
     (PROT-) PROTEOM LTD.
PA
XX
```

```
PΙ
    Roberts GW,
                 Heal JR;
XX
    WPI; 2001-408419/43.
DR
XX
    A set of peptide ligands consisting of specific complementary peptides to
PΤ
    proteins encoded by genes of the human genome, useful in an assay for
PT
PΤ
     screening and identifying of one or more novel peptides which are drug
    candidates or pro-drugs.
PT
XX
PS
    Example 6; Page 581; 646pp; English.
XX
CC
    The invention relates to a set of complementary peptide ligands generated
    from the human genome. The complementary peptides interact with their
CC
CC
    relevant target proteins encoded in the human genome. They can be used as
    reagents in drug discovery and as lead ligands to facilitate drug design
CC
     and development. The present sequence is a complementary peptide provided
CC
CC
     in the specification
XX
SQ
     Sequence 10 AA;
 Query Match
                           1.0%; Score 8; DB 1;
                                                  Length 10;
 Best Local Similarity 100.0%; Pred. No. 8.6;
 Matches
            8; Conservative 0; Mismatches
                                                   0;
                                                       Indels
                                                                 0;
                                                                    Gaps
                                                                             0;
Qу
         525 AGASAGAS 532
              Db
            1 AGASAGAS 8
Search completed: March 17, 2009, 20:59:10
```

Job time : 136 secs